Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruben Van Dijck

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Lancet. Haematology|April 2, 2025
Fedratinib for patients with myelofibrosisRuben Van Dijck, John-John Schnog, Peter Te Boekhorst
British Journal of Haematology|April 24, 2026
A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myelomaJohn-John B Schnog, Zoran Erjavec, Ruben Van Dijck
American Journal of Hematology|May 29, 2025
Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is UndefinedRuben Van Dijck, Zoran Erjavec, John-John B Schnog
Cancers|April 30, 2021
The Role of Rituximab in the Treatment of Primary Central Nervous System LymphomaRuben Van Dijck, Jeanette K Doorduijn, Jacoline E C Bromberg
The New England Journal of Medicine|April 12, 2023
Luspatercept as Potential Treatment for Congenital Sideroblastic AnemiaRuben Van Dijck, Alice M Goncalves Silva, Anita W Rijneveld
Haematologica|September 25, 2025
Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosisRuben Van Dijck, John-John B Schnog, Peter A W Te Boekhorst
Ejhaem|July 6, 2021
COVID-19-associated pseudothrombocytopeniaRuben Van Dijck, Mandy N Lauw, Maurice Swinkels, et al.
Annals of Hematology|August 6, 2017
Blinatumomab in relapsed/refractory diffuse large B cell lymphomaRuben Van Dijck, Ann Janssens, Daan Dierickx, et al.
Blood|March 27, 2025
Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosisJuan Carlos Hernandez-Boluda, Adrian Mosquera Orgueira, Luuk Gras, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Lancet. Haematology|April 2, 2025
Fedratinib for patients with myelofibrosisRuben Van Dijck, John-John Schnog, Peter Te Boekhorst
British Journal of Haematology|April 24, 2026
A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myelomaJohn-John B Schnog, Zoran Erjavec, Ruben Van Dijck
American Journal of Hematology|May 29, 2025
Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is UndefinedRuben Van Dijck, Zoran Erjavec, John-John B Schnog
Cancers|April 30, 2021
The Role of Rituximab in the Treatment of Primary Central Nervous System LymphomaRuben Van Dijck, Jeanette K Doorduijn, Jacoline E C Bromberg
The New England Journal of Medicine|April 12, 2023
Luspatercept as Potential Treatment for Congenital Sideroblastic AnemiaRuben Van Dijck, Alice M Goncalves Silva, Anita W Rijneveld
Haematologica|September 25, 2025
Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosisRuben Van Dijck, John-John B Schnog, Peter A W Te Boekhorst
Ejhaem|July 6, 2021
COVID-19-associated pseudothrombocytopeniaRuben Van Dijck, Mandy N Lauw, Maurice Swinkels, et al.
Annals of Hematology|August 6, 2017
Blinatumomab in relapsed/refractory diffuse large B cell lymphomaRuben Van Dijck, Ann Janssens, Daan Dierickx, et al.
Blood|March 27, 2025
Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosisJuan Carlos Hernandez-Boluda, Adrian Mosquera Orgueira, Luuk Gras, et al.
Pageof 1